SANOFI Pricing & Demo

Are you from this Company?
SANOFI
Write a Review
Paris, Ile-de-France, France
2004
$10BN to $50BN
Enterprise
78 Likes
77 Buyers Negotiating
Summary
No Summary And Details

Popular Comparisons

Discussions

Strengths
  • +9
    Monovalent
  • +10
    Multivalent
  • +6
    DTP (diphtheria, pertussis, tetanus)
  • +12
    Hepatitis
  • +7
    Influenza
  • +9
    Meningococcal disease
  • +5
    Others
  • +10
    Polio
  • +14
    Varicella
  • +10
    Intradermal (ID)
  • +8
    Intramuscular (IM)
  • +7
    Oral
  • +11
    Subcutaneous (SC)
  • +11
    Conjugate Vaccines
  • +12
    Inactivated and subunit vaccines
  • +13
    Live attenuated vaccines
  • +5
    Recombinant vaccines
  • +14
    Toxoid Vaccine
  • +12
    Number of products in phase 2
  • +10
    Number of products in pipeline currently
Cautions
  • -13
    Number of products in phase 1
  • -11
    Number of products in phase 3
  • -8
    Breadth and Depth of Product Offerings
  • -9
    Focus on Product Innovation
  • -8
    Human Papilloma Virus
  • -13
    MMR (Measles-Mumps-Rubella)
  • -5
    Pnemococcal disease
  • -11
    Rotavirus
  • -9
    Intranasal
  • -11
    Product Pipeline
  • -10
    Route of Administration
I agree to 360Quadrants Terms of use and privacy policy
Success
info
Error
Company Size :
  Enterprise
  SME
  Startup
logo-360
  • saved

    You haven’t saved anything yet

    To save, search for Vendors by
    Name or Category, then tap the heart